VTViatris VTRS · NASDAQ
$19.20 +2.29% (+$0.43)
- Market cap
- $22.1B
- Enterprise value
- $34.8B
- P/E
- -
- Forward P/E
- 7.5x
- PEG
- -
- P/S
- 1.5x
- P/FCF
- 11.8x
- EV/EBITDA
- 13.2x
- ROIC
- -0.2%
- Gross margin
- 34.8%
- Net margin
- -2.8%
- Dividend yield
- 2.50%
- Payout ratio
- -
- Net debt/EBITDA
- 4.8x
- Beta
- 0.86
- Free float
- 99.4%
About the company
Viatris Inc. is a pharmaceutical company formed through the merger of two significant pharmaceutical firms. The company specializes in research, development, and manufacturing of prescription medicines, generic drugs, and biosimilars. Viatris offers a broad range of medications for various diseases, from common ailments to serious health conditions. The company is active in the global pharmaceutical market, providing treatment for millions of patients worldwide. Viatris focuses on improving accessibility and affordability of medicines and providing quality alternative treatment options. The company also invests in research for new drugs and treatment approaches to better address patients' healthcare needs. Viatris Inc. (VTRS) shares are an interesting choice for investors who follow the pharmaceutical sector and seek investment opportunities in a global pharmaceutical company with an extensive portfolio of medicines and research activities.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Scott Andrew Smith
Employees
30,000
Headquarters
Canonsburg
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: It beat profit estimates 7 times in the last 8 quarters.
- What to watch: Revenue fell by 4.2% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 13 USD is left as free cash.
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: Repaying its net debt would take 4.8 years of operating profit.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number